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We report a rare case of metastatic non-small-cell lung cancer in a 43-year-old woman with a history of smoking.
The tumor secreted human chorionic gonadotropin and its beta subunit (BetaHCG). The patient presented with
amenorrhea, a positive pregnancy test and chest pain. A physical examination and investigations revealed no
pregnancy, and it was determined that a paraneoplastic syndrome stemming from a pulmonary tumor was
responsible for the secretion of BetaHCG. This secretion decreased with tumor response to chemotherapy. Only a
few reports of paraneoplastic BetaHCG secretion can be found in the literature for several different cancers.
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The lung cancer mortality rate has been declining in
men, especially for those between age 35 and 44 years of
age. The decline mirrors a significant reduction in men’s
smoking habits. However, lung cancer mortality in
women has been increasing, especially in younger
women. Moreover, recent studies have shown that fe-
male smokers have a 10-year reduced lifespan compared
with their non-smoking counterparts [1]. Cancer diagno-
sis can be made from primary tumor, metastatic lesions
or, less commonly, paraneoplastic syndromes, primarily
encountered in lung cancer. Paraneoplastic syndromes
(neoplasm-associated alterations resulting from damage
to organs or tissues that are remote from the tumor site)
are rare. They occur in 8% of cancer patients and fre-
quently develop with advanced disease but may appear
earlier than symptoms of the primary tumor itself, lead-
ing to a cancer diagnosis [2]. We report here the case of
a young woman with a history of smoking who
presented with a beta human chorionic gonadotropin
(BetaHCG) paraneoplastic secretion, an indicator of
non-small-cell lung cancer. We subsequently present a* Correspondence: cecile.vicier@gmail.com
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A 43-year-old woman (gravida 2, para 1, abortion 1 in
2010) presented with amenorrhea, nausea, chest pain
and asthenia. Her medical history included a diagnosis
of hepatitis C 2 years ago, weaned heroin and cocaine
addiction and active tobacco addiction. She had smoked
two packs of cigarettes daily for a period of 20 years and
drank two glasses of wine per day. She had no treatment
or allergy.
When she presented at the hospital, pregnancy was
suspected because of a 2-month history of amenorrhea
and lack of consistent use of contraception. A qualitative
BetaHCG test was positive. Pelvic examination revealed
a normal sized uterus and normal adnexum. She had
neither bleeding nor pelvic pain.
Serums concentrations of BetaHCG, taken 2 days apart,
were 1,135 and 1,180 UI/l (negative value < 5 UI/l).
Because of the elevated serum BetaHCG level, with an ab-
normal increase, the patient underwent a pelvic ultra-
sound, which revealed an empty uterine cavity and
normal ovaries. Uterine curettage was performed and re-
vealed no chorionic villi. Therefore, a laparoscopy was
performed, which revealed a normal abdominal cavity,
eliminating an ectopic pregnancy diagnosis. A germ cell
tumor was then suspected. Despite two cycles oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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creased (3,393 UI/l). At the same time, the patient’s chest
pain worsened, leading to the performance of a chest radi-
ography (Figure 1), which revealed many lesions in both
lungs.
A computed tomography scan (Figure 2) confirmed
multiple pulmonary lesions. The most significant lesion
was on the right lung (23 mm) with ipsilateral hilar
node. A bone scan showed a paravertebral mass, which
explained the chest pain. The bronchoscopy was macro-
scopically normal. A lung biopsy was performed. Histo-
logical examination revealed a poorly differentiated
carcinoma, AE1-AE3 and CK7 positive, CK20, TTF1 and
OCT3-4 negative, with cytoplasmic vacuoles positive to
anti-HCG antibody. No EGFR or KRAS mutation or
ALK rearrangement was found, but an amplification of
the ALK gene was observed in 22% of the analyzed cells.
Moreover, blood tests were performed to evaluate the
presence of tumor markers and showed normal levels of
carbohydrate antigen 19–9 (CA19.9), neuron specific
enolase and alpha-fetoprotein. We noted a slightly in-
creased level of carcinoembrionic antigen (ACE = 8 ng/ml,
negative value < 5 ng/ml) and cytokeratin 19 fragment
(Cyfra21 = 4.32 ng/ml, negative value < 3 ng/ml).
The paravertebral mass was rapidly irradiated, and a
cisplatin-based chemotherapy was initiated. After three
courses of a cisplatin-vinorelbine regimen, a computed
tomography scan showed progressive disease in the lung,
and BetaHCG concentrations continued to increase
markedly. Chemotherapy was therefore modified; treat-
ment with docetaxel was initiated. After four courses, a
partial tumor response was obtained in the lung, but
brain metastases appeared. The BetaHCG concentrationFigure 1 Chest radiography at the diagnosis.dropped to 436 UI/L. The patient received whole-brain
radiotherapy and two additional cycles of docetaxel.
Once the disease was stabilized, she received an oral 1-
year maintenance treatment of erlotinib but ultimately
experienced tumor progression and died from complica-
tions of the disease.Discussion
This young female patient with a BetaHCG-secreting
non-small-cell lung cancer was initially believed to be
pregnant. We noticed an elevated BetaHCG concentra-
tion and amenorrhea. However, due to increasing chest
pain, pathologic thoracic radiography, a computed tom-
ography scan and lung biopsies were performed. We
eliminated a choriocarcinoma based on histological ex-
aminations, which showed a poorly differentiated carcin-
oma (AE1-AE3 and CK7 positive, CK20, TTF1 and
OCT3-4 negative). Moreover, after her abortion in 2010,
she had the return of her menstrual cycles for 1 year, the
pelvic examination was normal and uterine curettage re-
vealed no chorionic villi. The BetaHCG secretion was
suspected to be due to a paraneoplastic syndrome asso-
ciated with the primary tumor. Indeed, the BetaHCG
concentration as well as all lung lesions decreased in re-
sponse to second-line chemotherapy, indicating that the
BetaHCG secretion was due to a paraneoplastic syn-
drome related to her primary lung tumor.
Outside of pregnancy, a high level of BetaHCG may
appear in molar pregnancies, choriocarcinomas and
germ cell tumors such as testicular tumors or ovarian
tumors [3]. In these cases, the BetaHCG secretion is
considered a paraneoplastic syndrome.
Figure 2 Computed tomography scan at the initial diagnosis. (A) Parenchymal sequence. (B) Mediastinal sequence.
Vicier et al. World Journal of Surgical Oncology 2013, 11:228 Page 3 of 4
http://www.wjso.com/content/11/1/228Paraneoplastic syndromes are an extremely diverse
group of clinical aberrations that are associated with
non-invasive actions of tumors. They develop mainly in
hematologic malignancies and, to a lesser extent, with
thymoma and small-cell lung cancer. Although they may
affect a variety of systems, their target is the endocrine
system [2]. Their precise pathophysiologic mechanism is
still unknown but has been suggested to be ectopic se-
cretion by tumor cells. Moreover, paraneoplastic syn-
dromes are known to be present in about 10% of lung
cancer cases [4]. Cases in the literature have reported
several Cushing syndromes associated with lung cancers
and other malignancies [5-7].
Based on reports in the medical literature, paraneoplastic
syndromes involving BetaHCG secretion are very uncom-
mon. Paraneoplastic BetaHCG secretion has been reported
in cases of squamous cell carcinoma of the head and neck[8], phyllode tumors of the breast [9], clear cell renal cell
carcinoma [10], and leiomysarcoma [11].
BetaHCG secretion is rarely associated with lung can-
cer. Paraneoplastic syndrome has been described in a
squamous cell lung cancer [12], large-cell lung carcin-
oma (BetaHCG secretion = 206 mIU/l) [13] and three
cases of pulmonary adenocarcinoma [14,15]. In the two
last cases of pulmonary adenocarcinoma, the BetaHCG
level was 13 UI/l and 19 UI/l, respectively. These levels
are significantly lower than the level observed in our pa-
tient. Moreover, these studies examined the interpret-
ation of BetaHCG testing for women of childbearing age
before treatment and inclusion in clinical trials. Our re-
port focused on a different clinical problem. Given a
high level of HCG, the possibility of pregnancy must first
be eliminated, delaying tumor diagnosis and initiation of
appropriate therapy.
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cancer presentations and the diagnostic complexity of
tumors revealed by a paraneoplastic syndrome. Second-
ary amenorrhea and a high level of BetaHCG secretion
are not always associated with a germinal tumor and
may be related to a paraneoplastic syndrome, suggesting
immediate and extensive investigation in the context of
no pregnancy.
Conclusion
We diagnosed a lung adenocarcinoma in a young
woman based on the presence of BetaHCG secretion;
this is considered a rare paraneoplastic syndrome. The
patient had exceptionally high levels of BetaHCG com-
pared with other cases reported in the literature.
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